188Re-nimotuzumab

N/A

Report date: 2025/10/20 14:38:43

NME

Base Information

Drug Name188Re-nimotuzumab

Drug Alias NameNimotuzumab labeled with 188 Re

ClassificationRadiation-emitting products > Nuclides > Rhenium > 188ReRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists

TargetsEpidermal growth factor receptor erbB1

Therapy Area/IndicationsGlioma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCuba

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesCuban Center For Molecular Immunology

China Registration ClassN/A

Develop Information

Active CompaniesCuban Center For Molecular Immunology

Inactive CompaniesN/A

Active IndicationsGlioma

Inactive IndicationsN/A

Other Information

ATC CodeN/A